ProUroCare Medical Inc. (PUMD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ProUroCare Medical Inc. (PUMD) trades at $0.0001 with AI Score 46/100 (Grade C). ProUroCare Medical Inc. focuses on developing products for detecting and characterizing male urological prostate disease. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PUMD: PUMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PUMD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PUMD: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
ProUroCare Medical Inc. (PUMD) Healthcare & Pipeline Overview
ProUroCare Medical Inc., founded in 1999, operates within the medical devices sector, focusing on the development of the ProUroScan System for prostate imaging. The company aims to improve the detection and characterization of male urological prostate diseases, primarily through its agreements with Artann Laboratories Inc.
What Is the Investment Thesis for PUMD?
ProUroCare Medical Inc. presents a highly speculative investment opportunity, given its small market capitalization of $0.00B and the inherent risks associated with OTC-listed companies. The company's sole product, the ProUroScan System, targets the prostate disease detection market, but its commercial success is uncertain. Key value drivers hinge on the successful commercialization and adoption of the ProUroScan System by urologists. Growth catalysts include potential regulatory approvals and expanded licensing agreements. However, the company's high beta of 18.51 indicates extreme volatility, and the absence of dividends reflects its current financial state. Investors should carefully consider the risks associated with investing in a micro-cap OTC stock with limited financial resources.
Based on FMP financials and quantitative analysis
PUMD Key Highlights
Market capitalization of $0.00B, indicating a micro-cap company with high growth potential but also significant risk.
- Free cash flow of $0.00B, reflecting the company's current stage of development and reliance on external funding.
- Beta of 18.51, signifying extremely high volatility compared to the overall market.
- No dividend yield, consistent with a growth-oriented company reinvesting earnings.
- Focus on the ProUroScan System, a prostate imaging technology, indicating a niche market focus.
Who Are PUMD's Competitors?
PUMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PUMD's Key Strengths?
Specialized focus on prostate disease detection.
- Proprietary ProUroScan System technology.
- Licensing agreements with Artann Laboratories Inc.
What Are PUMD's Weaknesses?
Limited financial resources.
- Small market capitalization.
- Dependence on a single product (ProUroScan System).
- OTC listing indicates higher risk.
What Could Drive PUMD Stock Higher?
Potential regulatory approvals for the ProUroScan System in key markets.
- Expansion of licensing agreements with Artann Laboratories Inc. or other partners.
- Development and commercialization of next-generation prostate imaging technology.
- Increasing awareness and adoption of the ProUroScan System by urologists.
- Positive clinical trial results demonstrating the efficacy of the ProUroScan System.
What Are the Key Risks for PUMD?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies with greater resources.
- Technological obsolescence of the ProUroScan System.
- Regulatory hurdles and delays in obtaining approvals.
- Limited financial resources and dependence on external funding.
- High volatility and illiquidity due to OTC listing.
What Are the Growth Opportunities for PUMD?
- Expansion of ProUroScan System's Market Reach: ProUroCare has the opportunity to broaden the market penetration of its ProUroScan System. This involves targeting a wider network of urologists and medical facilities, both domestically and internationally. Success hinges on demonstrating the clinical value and cost-effectiveness of the ProUroScan System compared to existing diagnostic methods. The timeline for significant market expansion is estimated at 3-5 years, contingent on securing additional funding and regulatory approvals.
- Strategic Partnerships for Distribution: Forming strategic partnerships with established medical device distributors could significantly enhance ProUroCare's market access. Leveraging the existing distribution networks of larger companies can accelerate the adoption of the ProUroScan System. These partnerships could also provide access to new markets and customer segments. The timeline for establishing such partnerships is projected at 1-2 years, depending on the negotiation and due diligence processes.
- Development of Next-Generation Prostate Imaging Technology: Investing in the research and development of next-generation prostate imaging technology can provide ProUroCare with a competitive edge. This could involve incorporating artificial intelligence and machine learning to enhance the accuracy and efficiency of the ProUroScan System. The timeline for developing and commercializing new technologies is estimated at 3-5 years, requiring substantial investment in R&D.
- Securing Regulatory Approvals in Key Markets: Obtaining regulatory approvals, such as FDA clearance in the United States and CE marking in Europe, is crucial for expanding the commercial reach of the ProUroScan System. These approvals validate the safety and efficacy of the technology, increasing its credibility and market acceptance. The timeline for securing regulatory approvals varies depending on the specific market and regulatory requirements, typically ranging from 1-3 years.
- Licensing Agreements for Technology Transfer: Exploring licensing agreements with other medical device companies or research institutions can generate revenue and expand the application of ProUroCare's technology. This involves granting rights to use the ProUroScan System or its underlying technology in specific applications or geographic regions. The timeline for establishing licensing agreements is estimated at 1-2 years, contingent on identifying suitable partners and negotiating favorable terms.
What Are PUMD's Competitive Advantages?
- Proprietary ProUroScan System technology.
- Licensing, development, and commercialization agreements with Artann Laboratories Inc.
- Focus on a niche market within prostate disease detection.
What Does PUMD Do?
ProUroCare Medical Inc., established in 1999, is dedicated to the development of innovative solutions for the detection and characterization of male urological prostate diseases. The company's core product is the ProUroScan System, an advanced prostate imaging system designed to assist physicians in identifying and documenting abnormalities in the prostate that have been initially detected through a digital rectal exam. This technology aims to provide a more detailed and accurate assessment of prostate health, potentially leading to earlier and more effective interventions. ProUroCare's business model centers around the licensing, development, and commercialization of its ProUroScan System. A key aspect of its strategy involves collaborative agreements with Artann Laboratories Inc., which likely contributes to the development and distribution of the ProUroScan System. The company's focus remains on enhancing the diagnostic capabilities for prostate diseases, addressing a significant need in men's healthcare. Based in Eden Prairie, Minnesota, ProUroCare Medical Inc. continues to navigate the medical device landscape with its specialized technology.
What Products and Services Does PUMD Offer?
- Develop products for the detection of male urological prostate disease.
- Develop products for the characterization of male urological prostate disease.
- Offer the ProUroScan System, a prostate imaging system.
- Aid physicians in documenting abnormalities in the prostate.
- Utilize digital rectal exams to detect abnormalities.
- Engage in licensing agreements for the ProUroScan System.
- Engage in development agreements for the ProUroScan System.
- Engage in commercialization agreements for the ProUroScan System.
How Does PUMD Make Money?
- Develop and commercialize the ProUroScan System for prostate imaging.
- Generate revenue through licensing, development, and commercialization agreements.
- Collaborate with Artann Laboratories Inc. for product development and distribution.
What Industry Does PUMD Operate In?
ProUroCare Medical Inc. operates within the medical device industry, specifically targeting the market for prostate disease detection and characterization. This market is driven by the increasing prevalence of prostate cancer and other urological conditions, as well as advancements in diagnostic technologies. The competitive landscape includes established medical device companies and specialized firms offering various prostate imaging and diagnostic solutions. ProUroCare's ProUroScan System aims to differentiate itself by providing a more detailed assessment of prostate abnormalities detected during digital rectal exams.
Who Are PUMD's Key Customers?
- Urologists
- Medical facilities
- Hospitals
Company Profile
ProUroCare Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Eden Prairie, US. The company is led by CEO Benjamin Banks. PUMD has traded publicly since 2022.
ProUroCare Medical Inc. (PUMD) Valuation Context
Relative to its peer group, PUMD's quantitative score of 46/100 is below the peer average of 65/100.
Key Financial Metrics
Return on equity for ProUroCare Medical Inc. stands at 90.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
ProUroCare Medical Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PUMD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on prostate disease detection.
- Proprietary ProUroScan System technology.
- Licensing agreements with Artann Laboratories Inc.
- Upcoming: Potential regulatory approvals for the ProUroScan System in key markets.
Bear Case
- Limited financial resources.
- Small market capitalization.
- Dependence on a single product (ProUroScan System).
- OTC listing indicates higher risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PUMD Latest News
No recent news available for PUMD.
PUMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PUMD.
Price Targets
Wall Street price target analysis for PUMD.
PUMD MoonshotScore
What does this score mean?
The MoonshotScore rates PUMD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
PUMD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ProUroCare Medical Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited or no financial reporting, making it difficult to assess the company's financial health.
- Low trading volume and liquidity, leading to wide bid-ask spreads and potential price volatility.
- Higher risk of fraud or manipulation due to the lack of regulatory oversight.
- Potential for delisting or suspension of trading.
- Limited access to capital and funding opportunities.
- Verify the company's registration and legal status.
- Attempt to locate and review any available financial statements or disclosures.
- Assess the company's management team and their experience.
- Research the company's products or services and their market potential.
- Evaluate the company's competitive landscape and its ability to compete.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 1999.
- Focus on developing a specific medical device (ProUroScan System).
- Has licensing, development, and commercialization agreements with Artann Laboratories Inc.
PUMD Healthcare Stock FAQ
What does the AI Score mean for PUMD?
PUMD holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. ProUroCare Medical Inc. focuses on developing products for detecting and characterizing male urological prostate disease. Its primary offering is the ProUroScan System, a prostate imaging system …
What does ProUroCare Medical Inc. do?
ProUroCare Medical Inc. specializes in the development and commercialization of medical devices for the detection and characterization of prostate diseases. Its primary product, the ProUroScan System, is designed to assist physicians in identifying and documenting abnormalities in the prostate that have been initially detected through a digital rectal exam.
What do analysts say about PUMD stock?
As of 2026-03-16, there is no available analyst coverage or consensus for ProUroCare Medical Inc. (PUMD) due to its OTC listing and small market capitalization. Key valuation metrics are not readily available, and growth considerations are highly speculative. Investors should conduct their own thorough research and due diligence before considering an investment in PUMD. The absence of analyst coverage reflects the high-risk nature of this investment.
What are the main risks for PUMD?
ProUroCare Medical Inc. faces several significant risks, including limited financial resources, dependence on a single product (ProUroScan System), and competition from established medical device companies. The company's OTC listing indicates higher risk due to limited regulatory oversight and potential illiquidity. Technological obsolescence and regulatory hurdles also pose potential threats. Investors should carefully consider these risks before investing in PUMD.
What are the key factors to evaluate for PUMD?
ProUroCare Medical Inc. (PUMD) holds an AI score of 46/100 (low). presents a highly speculative investment opportunity, given its small market capitalization of $0.00B and the inherent risks associated with OTC-listed companies. Not financial advice.
How frequently does PUMD data refresh on this page?
PUMD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PUMD's recent stock price performance?
ProUroCare Medical Inc. (PUMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on prostate disease detection. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PUMD overvalued or undervalued right now?
ProUroCare Medical Inc. (PUMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PUMD before investing?
Before investing in ProUroCare Medical Inc. (PUMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's OTC listing.
- Financial data is based on the provided information and may not be comprehensive.